Aura Biosciences, Inc. (NASDAQ:AURA) Given Average Rating of "Buy" by Brokerages

Aura Biosciences, Inc. (NASDAQ:AURA - Get Free Report) has received an average rating of "Buy" from the seven analysts that are currently covering the firm, Marketbeat reports. Five analysts have rated the stock with a buy recommendation and two have given a strong buy recommendation to the company. The average 12 month price objective among brokerages that have issued ratings on the stock in the last year is $23.00.

Separately, Lifesci Capital raised shares of Aura Biosciences to a "strong-buy" rating in a research report on Friday, January 31st.

Insiders Place Their Bets

In other Aura Biosciences news, insider Los Pinos Elisabet De sold 15,955 shares of the stock in a transaction on Tuesday, January 21st. The shares were sold at an average price of $7.67, for a total transaction of $122,374.85. Following the sale, the insider now directly owns 304,692 shares of the company's stock, valued at approximately $2,336,987.64. This represents a 4.98 % decrease in their ownership of the stock. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is available at the SEC website. Insiders sold a total of 23,045 shares of company stock valued at $177,242 in the last ninety days. Corporate insiders own 5.40% of the company's stock.

Institutional Investors Weigh In On Aura Biosciences

A number of institutional investors have recently modified their holdings of AURA. Long Focus Capital Management LLC boosted its stake in Aura Biosciences by 123.9% in the fourth quarter. Long Focus Capital Management LLC now owns 2,537,774 shares of the company's stock valued at $20,861,000 after acquiring an additional 1,404,228 shares during the period. Levin Capital Strategies L.P. boosted its position in Aura Biosciences by 169.1% during the 4th quarter. Levin Capital Strategies L.P. now owns 1,247,619 shares of the company's stock valued at $10,255,000 after purchasing an additional 783,984 shares during the period. B Group Inc. acquired a new stake in Aura Biosciences in the fourth quarter worth $3,885,000. Franklin Resources Inc. lifted its stake in Aura Biosciences by 14.8% in the third quarter. Franklin Resources Inc. now owns 1,668,960 shares of the company's stock valued at $15,571,000 after buying an additional 215,597 shares during the last quarter. Finally, Ensign Peak Advisors Inc boosted its holdings in shares of Aura Biosciences by 43.3% during the fourth quarter. Ensign Peak Advisors Inc now owns 390,695 shares of the company's stock valued at $3,212,000 after acquiring an additional 118,000 shares during the period. Institutional investors own 96.75% of the company's stock.

Remove Ads

Aura Biosciences Stock Performance

Shares of NASDAQ:AURA traded down $0.07 during mid-day trading on Monday, hitting $7.42. 110,016 shares of the company traded hands, compared to its average volume of 147,689. The firm has a market cap of $370.64 million, a P/E ratio of -4.29 and a beta of 0.30. The firm's 50 day simple moving average is $7.67 and its 200 day simple moving average is $8.66. Aura Biosciences has a 52-week low of $6.63 and a 52-week high of $12.38.

About Aura Biosciences

Aura Biosciences, Inc, a clinical-stage biotechnology company, develops precision immunotherapies to treat a range of solid tumors. The company's proprietary platform enables the targeting of a range of solid tumors using virus-like particles conjugated with drugs or loaded with nucleic acids to create virus-like drug conjugates.